Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melanie Chartier

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Clinical and Experimental Rheumatology|March 31, 2018
Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspectiveMauro Galeazzi, Rieke Alten, Melanie Chartier, et al.
BMC Musculoskeletal Disorders|August 1, 2015
Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION studyHubert G Nüßlein, Rieke Alten, Mauro Galeazzi, et al.
Clinical Rheumatology|May 10, 2022
Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational studyRieke Alten, Xavier Mariette, René-Marc Flipo, et al.
BMC Musculoskeletal Disorders|January 14, 2014
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION studyHubert G Nüßlein, Rieke Alten, Mauro Galeazzi, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Clinical and Experimental Rheumatology|March 31, 2018
Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspectiveMauro Galeazzi, Rieke Alten, Melanie Chartier, et al.
BMC Musculoskeletal Disorders|August 1, 2015
Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION studyHubert G Nüßlein, Rieke Alten, Mauro Galeazzi, et al.
Clinical Rheumatology|May 10, 2022
Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational studyRieke Alten, Xavier Mariette, René-Marc Flipo, et al.
BMC Musculoskeletal Disorders|January 14, 2014
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION studyHubert G Nüßlein, Rieke Alten, Mauro Galeazzi, et al.
Pageof 2